Comparing GLP-1, Tirzepatide, and SGLT-2 Drugs for Fatty Liver Disease | Research

The takeaway

Network meta-analysis compares the efficacy and safety of GLP-1 receptor agonists, tirzepatide, and SGLT-2 inhibitors for metabolic liver disease including NAFLD and NASH.

3 drug classes ranked
GLP-1 RAs, tirzepatide, and SGLT-2 inhibitors compared for liver outcomes via network meta-analysis

What the researchers found

Network meta-analysis provides comparative efficacy rankings of GLP-1 RAs, tirzepatide, and SGLT-2 inhibitors for NAFLD/NASH treatment, enabling indirect comparisons across drug classes.

Why it matters

No drug is currently FDA-approved specifically for NAFLD/NASH. Understanding which existing metabolic drugs best improve liver outcomes could guide off-label use and future trial design.

How the study worked

Systematic literature review and network meta-analysis of controlled trials from MEDLINE, EMBASE, and Cochrane databases, reported per PRISMA guidelines.

What this study cannot tell us

Network meta-analysis relies on indirect comparisons. Included trials may use different liver endpoints and follow-up durations. Not all trials were designed primarily for liver outcomes.

How to read the evidence

Systematic review and network meta-analysis — high-quality evidence synthesis, though limited by indirect comparisons and heterogeneous liver endpoints.

When this study was published

Published in 2026; includes trials through November 2024.

The bigger picture

As metabolic liver disease becomes one of the most common causes of liver transplantation, repurposing existing metabolic drugs offers the fastest path to effective treatment.

Questions still open

Will tirzepatide receive a specific FDA indication for NASH/NAFLD?
Should patients with fatty liver disease preferentially receive GLP-1 drugs over SGLT-2 inhibitors?

Common questions

Which drug is best for fatty liver disease?

This meta-analysis compares three drug classes, but results depend on specific outcomes measured. GLP-1 drugs and tirzepatide show promise for liver fat reduction, while SGLT-2 inhibitors offer additional metabolic benefits.

Is there an approved drug for fatty liver disease?

As of 2026, resmetirom (Rezdiffra) was approved for NASH with fibrosis, but GLP-1 drugs and tirzepatide are increasingly used off-label based on positive trial data for liver fat reduction.

Read the original research

Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.

British journal of clinical pharmacology

View on PubMed ↗Publisher’s paper ↗

Citation

Belančić, Andrej; Antza, Christina; Poutachidis, Anastasios; Palaska, Smaro; Gkrinia, Elvira Meni Maria; Faour, Andrea Katrin; Sener, Yusuf Ziya; Sener, Seher; Sultana, Rehena. (2026). Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.. British journal of clinical pharmacology. https://doi.org/10.1002/bcp.70492